Tenax Faces Make-or-Break Phase 3 Heart Failure Readout — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tenax Therapeutics is set to report Phase 3 results later this month for an oral treatment targeting a form of heart failure associated with high blood pressure in the lungs.
- The readout is described as one of the biggest binary stock events remaining on this year's biotech calendar, with Tenax's stock potentially doubling or more on a hit.
- On a negative outcome, Tenax's shares could fall to cash levels, given the company has no other drug candidates or indications to fall back on.
- The article flags that the proposed mechanism by which Tenax's drug might work is unproven, data from a prior study were mixed, and the disease itself is complicated.
- Tenax's entire corporate future rests on this single drug and indication, with the situation described as a 'crapshoot.'
Why it matters: Tenax is a single-asset company with no pipeline fallback, making this Phase 3 readout the sole determinant of its near-term corporate viability — investors face a doubling or near-total wipeout depending on the outcome, making it one of the highest-stakes binary events left in biotech this year.
Ask SkimNews
